Summary
Cten (C-terminal tensin-like) is a member of the tensin protein family found in complex with integrins at focal adhesions. It promotes epithelial-mesenchymal transition (EMT) and cell motility. The precise mechanisms regulating Cten are unknown, although we and others have shown that Cten could be under the regulation of several cytokines and growth factors. Since transforming growth factor beta 1 (TGF-β1) regulates integrin function and promotes EMT/cell motility, we were prompted to investigate whether TGF-β1 induces EMT and cell motility through Cten signalling in colorectal cancer. TGF-β1 signalling was modulated by either stimulation with TGF-β1 or knockdown of TGF-β1 in the CRC cell lines SW620 and HCT116. The effect of this modulation on expression of Cten, EMT markers and on cellular function was tested. The role of Cten as a direct mediator of TGF-β1 signalling was investigated in a CRC cell line in which the Cten gene had been deleted (SW620 ΔCten ).
When TGF-β1 was stimulated or inhibited, this resulted in, respectively, upregulation and downregulation of Cten expression and EMT markers (Snail, Rock, Ncadherin, Src). Cell migration and cell invasion were significantly increased following TGF-β1 stimulation and lost by TGF-β1 knockdown. TGF-β1 stimulation of the SW620 ΔCten cell line resulted in selective loss of the effect of TGF-β1 signalling pathway on EMT and cell motility while the stimulatory effect on cell proliferation was retained. These data suggested Cten may play an essential role in mediating TGF-β1-induced EMT and cell motility and may therefore play a role in metastasis in CRC.
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and is thought to play a critical role in cellular processes such as cell motility. 1 Cten is a putative biomarker in many cancers, acting as an oncogene in most tumour types including the colon, breast, pancreas and melanoma, and it is particularly associated with metastatic disease. 2 Cten expression is possibly upregulated through the activation of upstream signalling pathways since so far, no mutations or amplification of Cten in cancers has been documented. A study by Katz et al. showed that stimulation with EGF led to upregulated Cten expression at transcriptional level in breast cell lines, whereas others have shown that Cten is upregulated by the EGFR at posttranscriptional level. 3, 4 Further reports suggested that Cten is regulated by KRAS in both CRC and pancreatic cancer cells. 5 Cten expression was also shown to be negatively regulated by STAT3 in CRC cell lines, whereas others have found that Cten is upregulated by STAT3 in human lung cancer cells. 6, 7 How
Cten is activated and regulated in these tumours is unclear; nonetheless, multiple pathways seem to be involved, and it appears to be largely dependent on tissue type or context. Transforming growth factor beta 1 (TGF-β1) is a polypeptide member of the growth factor family that plays a physiological role in the regulation of wound healing, angiogenesis, differentiation and proliferation. TGF-β1 can function as a tumour suppressor in normal epithelial cells and in the early stage of cancer. However, the growth inhibitory function of TGF-β1 is selectively lost in late-stage cancer which results in an induction of cell migration, invasion and metastasis. 8, 9 Previous studies have shown that TGF-β1 is involved in the regulation of EMT processes through numerous downstream pathways, including Ras/MAPK, 10 RhoA
11
and Jagged 1/Notch. 12 TGFβ1 has also been found to signal through FAK to upregulate EMT-related mesenchymal and invasiveness markers and delocalize E-cadherin from the cell membrane. 13 TGF-β1 has been shown to regulate several integrins including αV, β1 and β3 in glioblastoma, fibroblast and kidney epithelial cells. 14 Others have suggested that the positive regulation of integrin αV, α6, β1 and β4 by TGF-β1 signalling is probably mediated via the activation of the TGF-β1/TGF-βRI/Smad2 signalling pathway. 15 Furthermore, the TGF-β1-mediated Smad signalling pathway has been shown to play an important role in EMT associated with metastatic progression. 10 A study by Hung et al. has also reported that TGF-β1 induces Cten upregulation in a dose-dependent manner and FGF2 mediates Cten-induced motility; however, the role of Cten in TGF-β1-mediated EMT and motility was not explored. 16 There are therefore several cellular functions and processes which are similarly regulated by Cten and TGF-β1. Both molecules seem to use FAK as a downstream messenger. However, a possible role of Cten in TGF-β1-mediated EMT and cell motility in CRC cells has not yet been postulated. Therefore, it was hypothesized that TGF-β may induce cell motility and promote EMT processes through the Cten signalling pathway.
| MATERIALS AND METHODS

| Cell culture
This work was performed in CRC cell lines HCT116 and SW620, which were a kind gift from Prof Ian Tomlinson. This work was also carried out in SW620
ΔCten cell line which was previously established by our group. 17 All cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) GlutaMAX ™ supplement (Thermo Fisher Scientific, Carlsbad, CA) antibiotic-free supplemented with 10% foetal bovine serum (FBS) (Sigma, St. Louis, MO) and maintained at 37°C in a 5% CO 2 atmosphere. Cell line identities were authenticated by STR profiling.
| Cell transfection
Cells were transfected with small interfering RNA (siRNA) targeted to TGF-β1 (CCA CCU GCA AGA CUA UCG ACA UGG A) or luciferase (CGU ACG CGG AAU ACU UCG A) as a negative control using Lipofectamine 2000 (Invitrogen, Paisley, UK) according to the manufacturer's protocol. Cells were grown to 40%-50% confluency, and siRNA duplexes were added at a final concentration of 10 nM and 10 μL of Lipofectamine 2000 to each well of a 6-well plate. The cells were incubated with the transfection reagents for 6 hours and experiments performed 48 hours post-transfection.
| Cell treatment
In order to stimulate TGFβ1 signalling, cells were seeded into a six-well plate and starved in serum-free DMEM for 24 hours at 37°C prior to stimulation. Cells at 50%-60% confluency were treated with 0-20 ng/mL Recombinant Human TGFβ1 (R&D Systems, Minneapolis, MN) in DMEM growth media (supplemented with 10% FBS), with a total volume of 2 mL per well. After optimization in a time course from 24 to 96 hours, cells were harvested after incubation for 48 hours since this was considered the appropriate duration of TGFβ1 stimulation that caused expected changes in EMT markers.
| Western blot
Cell lysates were prepared using RIPA lysis buffer (Thermo Fisher Scientific) supplemented with phosphatase and protease inhibitor (Thermo Fisher Scientific). Fifty micrograms of protein was added to NUPAGE LDS Sample Buffer (Thermo Fisher Scientific) containing 5% β-mercaptoethanol. The protein samples were heated to 90°C on a heat block for 5 minutes and cooled on ice for another 5 minutes. Following this, the protein samples were fractionated on a precast 4%-12% NUPAGE Bis-Tris-HCl buffered (pH 6.4) polyacrylamide gel (Thermo Fisher Scientific) using the NUPAGE gel electrophoresis system with NUPAGE MOPS SDS Running Buffer (Thermo Fisher Scientific, Carlsbad, CA) at 125 V for 90 minutes. Proteins were then transferred on to PVDF membrane (GE Life Sciences) using the Trans-Blot semi-dry transfer system (Bio-Rad Laboratories, Hertfordshire, UK). Following blocking in 5% milk or 5% BSA in 0.1% Tween PBS or 0.1% Tween TBS (dependent on antibody diluents), membranes were incubated with optimally diluted primary antibodies overnight at 4°C (Table S1 ). Following washing, membranes were incubated with the appropriate anti-mouse or anti-rabbit secondary antibody for 1 hour at room temperature (Table S1 ). The ECL prime detection kit (GE Life Sciences) was used for protein band visualization using the CDiGiT Blot Scanner (LI-COR, Lincoln, NE). Densitometric analysis of the bands was performed using ImageJ software. Pixel counts for each protein of interest were normalized to β-actin.
| Cell viability assay
PrestoBlue Cell Viability Reagent (Thermo Fisher Scientific) was used as an indirect method to measure the total number of live cells. Briefly, 5 × 10 3 cells were seeded into a 96-well plate and allowed to attach for 24 hours. Following this, 100 μL of PrestoBlue Cell Viability Reagent was added to the cells and without cells as control and incubated for 1 hour at 37°C. Following incubation, the relative fluorescent units of each well of the 96-well plate were then measured using the BMG FLUOstar Optima Plate reader (540 nm excitation/590 nm emission). Further readings were taken at 48-and 72-hour time points. The blank fluorescence reading was subtracted from each experimental fluorescence reading, and the blank corrected values were then normalized to the 24-hour time point.
| Transwell migration and invasion assays
The changes in cell migration were assessed in 24-well plates using the Transwell system (Corning, NY). Cells were treated with mitomycin C (10 μg/mL) for 3 hours and washed 3 times with PBS to inhibit cell proliferation. The Transwell inserts (6.5 mm diameter; 8 μm pore size) were incubated in DMEM at 37°C for 1 hour prior to use. Following this, 600 μL of DMEM (20% FBS) was added to the outer wells of the Transwell plate and the Transwell inserts placed inside. A total of 1 × 10 5 cells in DMEM (10% FBS) were seeded onto the Transwell insert. The plate was incubated at 37°C for 24 hours. Following this, the cells that had migrated through to the bottom of the outside well, using the higher FBS concentration as a chemoattractant, were manually counted.
Triplicate wells were seeded for each experimental condition. The Transwell invasion assay was performed according to this protocol with the exception that 2 × 10 5 cells were seeded onto a Transwell insert coated in Matrigel reduced growth factor at 0.3 mg/mL (Corning, NY) and cells allowed to migrate for 48 hours prior to counting.
| Wound healing
Wound healing scratch assay was performed as an alternative assay to assess cell migration. Briefly, 5-7 × 10 5 cells/mL were seeded into culture-insert 2 well (Ibidi, Martinsried, Germany) attached in 6-well plates and incubated for 24 hours at 37°C until they reached confluency. After cell attachment, the culture inserts were removed, and the cells were treated with mitomycin C (Sigma, St. Louis, MO) at 10 μg/mL for 3 hours to inhibit proliferation and remove any influence different proliferation rates could have in the apparent migration of TGFß-treated cells. Cells were then cultured under normal conditions, and the pictures were taken at 0, 24 or 48 hours using an inverted microscope (Nikon, Surrey, UK) at 10x magnification. The width of the cellfree gap was approximately 500 microns (±50 microns) at time 0 hour. Experiments were performed in duplicate and on at least on two separate occasions. Cell migration was assessed by measuring the remaining open area of the wound by ImageJ software.
| Statistical analysis
Results were tested for a normal distribution, and the unpaired t-test or analysis of variance (ANOVA) statistical tests were applied using GraphPad Prism (version 6). For both ANOVA and unpaired t-test, a two-tailed value of P < 0.05 was deemed to have statistical significance.
| RESULTS
| TGF-β1 regulates Cten expression
Both TGF-β1 and Cten induce EMT and cell motility and are associated with integrin signalling. Thus, it was of interest to determine whether Cten expression is under the regulation of the TGF-β1 signalling pathway in CRC cells. After a timecourse experiment lasting up to 96 hours, a 48-hour endpoint was selected for stimulation with TGF-β1 as this was sufficient to produce expected changes in EMT markers (data not shown). SW620 cells were then treated with different concentrations of TGF-β1-human recombinant protein from 0 to 20 ng/mL for 48 hours, and the changes in protein level of Cten and its downstream targets, ROCK1, N-cadherin, E-cadherin, Src and Snail were evaluated by Western blot. SW620 cells showed a dose-dependent increase in Cten, ROCK1, Src, Snail and Ncadherin expression, whereas the protein expression level of E-cadherin was decreased following stimulation with TGF-β1
( Figure 1A) . The optimum concentration of TGF-β1-human recombinant protein (20 ng/mL) was selected for subsequent TGF-β1 stimulation experiments. In SW620, cell migration, invasion and proliferation were increased when cells were treated with TGF-β1-human recombinant protein compared to untreated control ( Figure 1B-E) .
The relationship between TGF-β1 and Cten was further investigated in an additional cell line, HCT116. In agreement with the findings in SW620 cells, stimulation of TGF-β1 was associated with an increase in the protein expression levels of Cten, ROCK1, Src, Snail and N-cadherin, whereas E-cadherin expression was inhibited (Figure 2A) . The ability of TGF-β1 to alter cell motility and viability was then investigated using the Transwell migration assay, wound healing assay, Transwell Matrigel invasion assay and cell viability assay. In HCT116 cell lines, cell migration, invasion and proliferation were increased when cells were treated with TGF-β1-human recombinant protein compared to untreated control ( Figure 2B-E) .
The effect of TGF-β1 on Cten and its downstream targets was again investigated in SW620 cell but using an alternative methodology. Assuming that there was some endogenous production of TGF-β1 by the cell lines, this was transiently knocked down by siRNA and changes in protein expression level of Cten, ROCK1, Src, Snail, Ecadherin and N-cadherin were evaluated by Western blot.
Confirming the TGF-β1 stimulation results, knockdown of TGF-β1 resulted in a reduction of Cten, ROCK1, Src, Snail, N-cadherin protein expression levels. Additionally, TGF-β1 knockdown was associated with an increase in the expression level of E-cadherin compared to luciferasetargeting siRNA control ( Figure 3A) . The effect of TGF-β1 knockdown on cell functions was also tested in this study ( Figure 3B-E) . Knockdown of TGF-β1 was associated with a significant decrease in cell migration, invasion and proliferation compared to the luciferase control ( Figure 3B-E) . Collectively, these findings suggest that TGF-β1 may promote both cell motility and proliferation through the upregulation of EMT processes in CRC cells.
| Cten deletion selectively abrogates TGF-β1-induced cell migration and invasion
Our data have shown that TGFβ1 is a positive regulator of Cten expression and a number of markers of EMT. We also showed that TGFβ1 signalling induces cell motility (both migration and invasion). Since Cten induces EMT and cell motility, it is reasonable to hypothesize that Cten is a direct mediator of TGFβ1 activity. We have previously described the creation of SW620 ΔCten . 17 This is derivative of SW620 in which Cten has been deleted using CRISPR/Cas9 technology. In order to test our hypothesis, SW620
ΔCten was stimulated with TGFβ1 and Western blotting was performed. The results revealed that stimulation with TGF-β1 was associated with a small increase in N-cadherin expression but ROCK1, Src,
Snail and E-cadherin protein expression level remained unchanged compared to the untreated cells control ( Figure 4A ). This implies that Cten may be responsible for TGF-β1-induced EMT. A direct comparison of SW620 and SW620 ΔCten protein levels of ROCK1, N-cadherin and Snail upon TGF-β1 stimulation at concentrations ranging 5-20 ng/mL is provided in Figure S1 . To determine whether Cten was functionally relevant to TGF-β1-mediated activity, SW620
ΔCten was stimulated by TGF-β1 and assays for Transwell migration, wound healing, Matrigel invasion and cell viability were performed ( Figure 4B-E) . The deletion of Cten in SW620 ΔCten cells resulted in an abrogation of the ability of TGF-β1 to induce cell migration or invasion while the ability to induce cell proliferation was retained. Thus, Cten appears not to be involved in TGF-β1-induced cell proliferation, but it may be a signalling intermediate in the TGF-β1/EMT pathway regulating cell migration and invasion in CRC cells ( Figure 5 ).
| DISCUSSION
Epithelial-mesenchymal transition is a critical process occurring during tumour metastasis. During the EMT process, 
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Transforming growth factor beta 1 stimulation causes upregulation of Cten and its downstream targets (Src, Rock1, Snail) and also N-cadherin; conversely, there is downregulation of E-cadherin which is characteristic of EMT. These changes in EMT biomarkers are coherent with increases in Cten-dependent cell motility and invasion. The effect TGFβ1 stimulation has on cell proliferation is independent of Cten signalling, as observed by using SW620 ΔCten ( Figure 4E) epithelial cells show loss of cell-to-cell adhesion by Ecadherin downregulation at adherens junctions, cytoskeleton reorganization via switching from keratin to vimentin intermediate filaments, loss of apical-basal polarity, acquisition of mesenchymal cell phenotype and increased cell invasion and migration. 18 Cten has been shown to act as an oncogene in most tumour types and to be involved in regulation of EMT processes; however, the mechanisms that upregulate the expression of Cten-induced EMT have not been elucidated. 17, [19] [20] [21] Research from our laboratory has suggested that Cten expression is regulated by EGFR/ KRAS signalling in pancreatic and colorectal cancer cell lines 5 validating a previous study by Katz et al. 3 showing the role of Her2 in upregulating Cten in breast cancer cell lines. Furthermore, we and others have also found that Cten could be under the regulation of several cytokines such as IL6/Stat3 6 and growth factors, including EGF, NGF and FGF2 which also induces cell motility. 16 The present study directly shows for the first time an essential role for Cten in TGF-β1-induced EMT and cell motility in CRC cells and that this may be through upregulation of the Src/ROCK1/ Snail signalling pathway. Transforming growth factor beta 1 reputedly plays a key role in promoting EMT initiation and tumour metastasis. In the latest classification of CRCs, 22 the most aggressive class (CMS4) is characterized by TGF-β activation. It has been documented that TGF-β1 induces the expression of several transcription factors including Twist, Zeb, Slug and Snail. 23 Here, using different methods of modulating TGF-β1 activity, we have shown that TGF-β1 is a positive regulator of Cten expression. We have also shown that TGF-β1 is a positive regulator of Src, ROCK and Snail expression. Since these are putative targets of Cten, it begs the question whether, in this case, they are directly upregulated by TGF-β1 signalling or whether they are upregulated by Cten as a secondary event. Using the SW620 ΔCten cell line (in which Cten is deleted), we were able to conclusively show that upregulation of these molecules is Cten-dependent. The mechanisms by which these proteins are upregulated are uncertain although we have previously shown that Cten causes post-translational stabilization of Snail. 17 The link between TGF-β1 and Cten may be through integrins since TGF-β1 induces integrin activation and Cten is found in complex with the cytoplasmic tail of integrins. However, there are also several other downstream targets of TGF-β1-mediated EMT which may possibly be involved in regulation of Cten and further investigation of markers/signalling pathways such as Ras/MAPK, 10 RhoA 11 and Jagged 1/ Notch 12 is warranted.
Our data suggest a novel downstream signalling pathway for TGF-β1 which is mediated through Cten. In order to ascertain whether this represented a functionally relevant pathway, we performed assays to assess motility (both by invasion and migration assays) and cell proliferation. In our models, TGF-β1 signalling was shown to increase cell proliferation, migration (both Transwell migration and wound healing) and cell invasion. These data are in accordance with previous studies that TGF-β1-induced EMT can promote cell motility and proliferation in a vast range of different tumour cells such as breast cancer and oral squamous cell carcinoma. 24, 25 Intuitively, one would think that the induction of cell motility was mediated through the Cten pathway. This was confirmed by our observation that there was a selective loss of the effect of TGF-β1 treatment on both cell migration and invasion in the SW620 ΔCten cell line while the effect of TGF-β1 treatment on cell proliferation was unaffected. This is completely in line with our previous data showing that Cten regulates cell motility and does not affect cell proliferation. 18 It is not unexpected that TGF-β1 will activate different signalling pathways to regulate different cellular functions. Our data show that the Cten pathway is an important factor in the TGF-β1 regulation of cell motility and they may explain other observations that have been made. Thus, previously published data from our group have shown that Cten induces EMT and promotes cell motility through FAK, ILK and Snail signalling. 16, 20, 26 Previously, it has been shown that FAK and/or ILK are required for TGF-β1-induced EMT and to promote cell motility. 13, 27 Snail also has been shown to act as a mediator of TGF-β1-induced EMT. 28 We would now hypothesize that Cten is one of the missing links which would explain FAK/ILK/Snail dependence of TGF-β1-induced cell motility. In addition to Cten, there are other downstream pathways involved in TGF-β1-mediated cell migration, including JAK/ STAT3, 29 PI3K-Akt 30 and Reelin, 31 so it would be of interest to determine whether Cten acts in parallel or synergistically with these pathways in future studies. In summary, the data presented have indicated that TGFβ1 and Cten signalling may cooperate in promoting EMT and cell motility. Regulation of downstream markers of EMT such as Src/ROCK1/Snail by TGFβ1 is dependent on Cten. These processes are relevant to the development of metastasis and our data open up the possibility of targeting Cten in CRC.
